Expanded Access to Provide LOXO-195 for the Treatment of Cancers With a NTRK Gene Fusion

Trial Profile

Expanded Access to Provide LOXO-195 for the Treatment of Cancers With a NTRK Gene Fusion

Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 19 Jul 2017

At a glance

  • Drugs LOXO 195 (Primary)
  • Indications Cancer
  • Focus Expanded access; Therapeutic Use
  • Sponsors Loxo Oncology
  • Most Recent Events

    • 19 Jul 2017 Last checked against ClinicalTrials.gov record.
    • 04 Jul 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top